KRAS(G12C)/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma

BACKGROUND: Pembrolizumab is a standard of care as first line palliative therapy in PD-L1 overexpressing (≥50%) non-small cell lung cancer (NSCLC). This study aimed at the identification of KRAS and TP53-defined mutational subgroups in the PD-L1 high population to distinguish long-term responders fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Frost, Nikolaj, Kollmeier, Jens, Vollbrecht, Claudia, Grah, Christian, Matthes, Burkhard, Pultermann, Dennis, von Laffert, Maximilian, Lüders, Heike, Olive, Elisabeth, Raspe, Matthias, Mairinger, Thomas, Ochsenreither, Sebastian, Blum, Torsten, Hummel, Michael, Suttorp, Norbert, Witzenrath, Martin, Grohé, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947421/
https://www.ncbi.nlm.nih.gov/pubmed/33718018
http://dx.doi.org/10.21037/tlcr-20-958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947421/
https://www.ncbi.nlm.nih.gov/pubmed/33718018
http://dx.doi.org/10.21037/tlcr-20-958

Ejemplares similares